Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in CD19+ malignancies. However, the etiological nature of neurologic complications remains a conundrum. In our study, the evidence of blood-brain barrier (BBB)-penetrating CAR T cells as a cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yongxian, Sun, Jie, Wu, Zhao, Yu, Jian, Cui, Qu, Pu, Chengfei, Liang, Bin, Luo, Yi, Shi, Jimin, Jin, Aiyun, Xiao, Lei, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986179/
https://www.ncbi.nlm.nih.gov/pubmed/27526682
http://dx.doi.org/10.1186/s13045-016-0299-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986179/
https://www.ncbi.nlm.nih.gov/pubmed/27526682
http://dx.doi.org/10.1186/s13045-016-0299-5

Ejemplares similares